Factors Associated with Changing the Low-Density Lipoprotein Cholesterol (LDL-C) among Patients with Ischemic Heart Disease Receiving Atorvastatin
Keywords:Low-Density Lipoprotein Cholesterol (LDL-C), Ischemic Heart Disease, Atorvastatin
The purpose of this prospective descriptive study was to investigate factors associated with changing the Low-Density Lipoprotein Cholesterol (LDL-C) among patients with ischemic heart disease receiving Atorvastatin. Sixty-six patients with ischemic heart disease who registered in treatment from March 1st, 2019 to March 31th, 2020 in Khunkhanun Hospital, Phatthalung Province, and receiving Atorvastatin were included in the study. Subjects were followed up and had a complete laboratory testing of LDL-C at baseline, 3 and 6 months. The data were analyzed using descriptive statistics, repeated-measures ANOVA and General Estimating Equation (GEE). The results revealed that factors; chronic kidney diseases (Mean difference = 16.24, 95%CI: 7.38 to 25.09); receiving Enalapril (-12.31, -20.31 to -4.31) and Losartan (25.32, 6.14 to 44.50; HbA1C (5.05, 3.22 to 6.88), hematocrit (2.09, 1.04 to 3.13) and creatinine (10.77, 4.11 to 17.43) were significantly associated with changing the LDL-C among patients with ischemic heart disease receiving Atorvastatin. It suggested that patients with ischemic heart disease who had high-level LDL-C need to be treated with Atovastatin in order to reduce the risk of relapses and mortality from ischemic heart disease.
Yusuf S, Reddy S, Ounpuu S & Anand S. Global burden of cardiovascular disease: Part II: variations in cardiovascular disease by specific ethnic groups and geographic gions and prevention strategies. Circulation. 2001; 104(23): 2855-2864.
World Health Organization. Non communicable Disease in the South-East Asia Region. [Internet]. 2011.[Accessed 2 November 2019]. Available from: http://w w w . s e a r o . w h o . i n t / e n t i t y / n o n communicabledisease/documents.
Porapakkham Y, Rao C & Pattaraaechachat J. Estimated causes of death in Thailand 2005 : Implications for health policy. Population Health Metrics. 2010; 8(14): 24-34.
Hyo-Soo K, Yangfeng W, Shing-Jong L, Chaicharn D, Robaayah Z & Liancheng Z. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Current Medical Research and Opinion. 2008; 24: 1951-1963.
Sukonthasarn A, Homsanit M, Prommete B, Chotinaiwattarakul C, Piamsomboon C, & Likittanasombat K. Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey. Journal of the Medicine Association Thailand. 2011; 94(12): 1424-1434.
Trialist C, Baigent C & Blackwell L. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet. 2010; 376: 1670-1681.
Law MR, Wald NJ & Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta - analysis . British Medical Journal. 2003; 326: 1423-1427.
Quehenberger O & Dennis EA. The human plasma lipidome. New England Journal Medicine. 2011; 365: 1812-1823
Khuankhanun Hospital. Khuankhanun Hospital Registration Report, Phatthalung Province. Khuankhanun Hospital, Khuankhanun District, Phatthalung. (2018). [in thai].
Khuankhanun Hospital. Monthly Report Summary Emergency and Accident work, Phatthalung Province. Khuankhanun Hospital, Khuankhanun District, Phatthalung. (2018). [in thai].
Brown MS & Goldstein JL. A receptormediated pathway for cholesterol homeostasis. Science. 1986; 232: 34-47.
Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery. 2003; 2: 517-526.
Goldberg IJ. Diabetic dyslipidemia: causes and consequences. Journal of Clinical Endocrinology & Metabolism. 2001; 86: 965-971.
Ray KK, Cannon CP & McCabe CH. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: result from the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology. 2005; 46: 1405-1410.
Mikolasevic I, Zutelija M & Mavrinac V. Dyslipidemia in patients with chronic kidney disease: etiology and management. International Journal of Nephrology and Renovascular Disease. 2017; 10: 35-45.
Batista MC, Welty FK & Diffenderfer MR. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism. 2004; 53: 1255-1261.
Dantoine TF, Debord J & Charmes JP. Decrease of serum paraoxonase activity in chronic renal failure. Journal of the American Society of Nephrology. 1998; 9: 2082-2088.
Mustafa C. Tuncay D. Baris A. Nuray N. Masanari K. Adrian C & Mehmet K. Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purification. 2018; 46: 144–152.
Kyvelou SM, Vyssoulis GP, Karpanou EA & A d a m o p o u l o s D N . E f f e c t s o f antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic Journal of Cardiology. 2006; 47: 21-28.
Andrew MT, William FK, Zhongxin Z & Paulette AL. Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study. Diabetes Care. 2008; 31: 445-447.
Ketema EB & Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Archives Public Health. 2015; 73(1): 43-48.
Gingberg HN. Insulin resistance and cardiovascular disease. Journal of Clinical Investigation. 2000; 106: 453-458.
Samdani TS, Mitra P & Rahim MA. Relationship of Glycated Haemoglobin with Lipid Profile among Patients with Type 2 Diabetes Mellitus. Birdem Medical Journal. 2017; 7: 43-47.
Hellerstein M & Turner S. Reverse cholesterol transport fluxes. Current Opinion Lipidology. 2014; 25: 40-47.
Campbell NR, Wickert W, Magner P & Shumak SL. Dehydration During Fasting Increases Serum Lipids and Lipoproteins. Clinical and Investigative Medicine. 1994; 17: 570-576.
Gabriel PR, Marcos AG & Leila A. Evaluation of relationship between hematocrit and lipid profile in adults. J Bras Patol Med Lab. 2018; 54:146-152.
Elzbieta K, Janusz S & Lucyna J. LIPOPROTEIN PROFILES AT DIFFERENT STAGES OF CHRONIC RENAL INSUFFICIENCY. Renal Failure. 2000; 22: 69-71.
Ahaneku JE, Sakata K & Urano T. Lipids, Lipoproteins and Fibrinolytic Parameters during Amlodipine Treatment of Hypertension. Journal of Health Science. 2000; 46: 455-458.
Saker H, Hamed A, Jamee A & Wadi M. Effect of Amlodipine Alone and in Combination with Enalapril on Lipid Profile in Hypertensive Patients with Chronic Kidney Disease (Gaza Strip). American Journal of Clinical and Experimental Medicine. 2016; 4: 146-150.
Masuo K, Mikami H, Ogihara T & Tuck ML. Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients. American Journal of Hypertension. 2006; 10: 600–10.
Saker H, Hamed A, Jamee A & Wadi M. Effect of Amlodipine Alone and in Combination with Enalapril on Lipid Profile in Hypertensive Patients with Chronic Kidney Disease (Gaza Strip). Journal of Clinical and Experimental Medicine. 2016; 4:146-150.